- $5.08m
- $3.29m
- $6.16m
Brief: Wallachbeth Capital announces pricing of Bioaffinity Technologies public offering for $4.8 mln
Brief: Bioaffinity Technologies Announces Pricing Of $4.8 Million Public Offering
Brief: bioAffinity Technologies Announces 1-For-30 Reverse Stock Split Effective At The Open Of Trading On September 19, 2025
Brief: Bioaffinity Technologies Appoints New Members To Board Of Directors
bioAffinity Technologies Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Case Study CyPath® Lung Detects Stage 1A Lung Cancer In High-Risk Patient With Inconclusive Imaging And Low-Risk Serum Test Results
Brief: bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
Brief: bioAffinity Technologies Announces New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics
bioAffinity Technologies Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Bioaffinity Technologies Increases Efficiency Of Cypath Lung Test
Brief: Bioaffinity Technologies Files For Resale Of Up To 3.0 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Bioaffinity Technologies Announces Acceptance Of Patent Application For Early-Stage Lung Cancer Diagnostic
Brief: BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development
Brief: bioAffinity Technologies CFO To Depart, J. Michael Edwards To Return As Interim CFO
Brief: bioAffinity Technologies Advances New Product Development Initiatives
Brief: Bioaffinity Technologies Filed Prospectus Relates To Resale From Time To Time Of Up To 1.6 Mln Shares Of Common Stock By Selling Stockholders
Brief: bioAffinity Technologies News Update
Brief: Bioaffinity Technologies Appoints Jamie Platt To Its Board Of Directors
Brief: CMS Posts Final Payment Determination For Bioaffinity Technologies’ Cypath® Lung Effective January 2024